Table 1:
Outcomes after flow-diversion treatment of unruptured nonsaccular intracranial aneurysms
| Variables | Results of Systematic Review and Meta-Analysis | No. of Articles | Statistic (95% CI) (I2) |
|---|---|---|---|
| Angiographic outcomes | |||
| Rate of successful stent deployment | 178/181 = 96% | 11 | (93–98) (I2 = 0%) |
| Long-term aneurysm adequate occlusion rate | 137/168 = 85.3% | 12 | (78.2–92.4) (I2 = 42.3%) |
| Long-term aneurysm complete occlusion rate | 128/168 = 78.8% | 12 | (72.8–84.8) (I2 = 0%) |
| Long-term adequate occlusion rate (fusiform aneurysms) | 116/146 = 83% | 11 | (74–92) (I2 = 48%) |
| Long-term adequate occlusion rate (dissecting aneurysms) | 33/36 = 89% | 4 | (80–98) (I2 = 0%) |
| Long-term occlusion rate among anterior circulation | 51/61 = 87.5% | 6 | (79–95) (I2 = 0%) |
| Long-term occlusion rate among posterior circulation | 86/107 = 83% | 6 | (71–95) (I2 = 60%) |
| Long-term adequate occlusion rate (PED) | 118/149 = 82% | 8 | (75–90) (I2 = 25%) |
| Long-term adequate occlusion rate (other devices) | 21/23 = 90% | 3 | (81–98) (I2 = 0%) |
| Treatment-related complications and clinical outcomes | |||
| Overall treatment-related complications | 41/213 = 17.4% | 16 | (12.5–22.4) (I2 = 0%) |
| Transient complications | 21/213 = 9% | 15 | (5.6–13) (I2 = 0%) |
| Permanent complications | 20/213 = 8% | 15 | (5–12) (I2 = 0%) |
| Ischemic complications | 37/213 = 15% | 15 | (10–20) (I2 = 0%) |
| Hemorrhagic complications | 4/213 = 3% | 15 | (1.2–6) (I2 = 0%) |
| Treatment-related complications (fusiform aneurysms) | 35/162 = 17% | 11 | (10–25) (I2 = 24%) |
| Treatment-related complications (dissecting aneurysms) | 11/51 = 19% | 4 | (10–31) (I2 = 0%) |
| Treatment-related complications among anterior circulation | 13/81 = 14% | 8 | (7–22) (I2 = 0%) |
| Treatment-related complications among posterior circulation | 28/132 = 20% | 8 | (3–13) (I2 = 0%) |
| Treatment-related complications (PED) | 19/110 = 15% | 9 | (9–21) (I2 = 0%) |
| Treatment-related complications (other devices) | 3/23 = 12% | 3 | (6–24) (I2 = 0%) |
| Periprocedural/early complications (within 30 days) | 10/213 = 2.5% | 15 | (1–4) (I2 = 0%) |
| Delayed complications (after 30 days) | 31/213 = 12% | 15 | (7–17) (I2 = 35%) |
| Premature discontinuation of AT and related ischemic events | 5/93 = 5% | 8 | (2–9) (I2 = 0%) |
| Treatment-related mortality | 1/213 = 2% | 15 | (0.2–3.5) (I2 = 0%) |
| Overall rate of good neurologic outcome | 154/187 = 87% | 10 | (79–95) (I2 = 60%) |
| Occlusion of covered branches | 5/72 = 7% | 10 | (2–13) (I2 = 0%) |
| Symptoms related to occlusion or impaired flow of covered branches | 3/72 = 3% | 10 | (0.5–9) (I2 = 0%) |
Note:—AT indicates antiplatelet therapy.